Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional Post Authorization Study (PASS) to Evaluate Long-term Safety of Orfadin Treatment in Hypertyrosinemia Type 1 (HT-1) Patients in Standard Care

NCT02320084 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.

NCT NCT02320084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02320084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional Post Authorization Study (PASS) to Evaluate Long-term Safety of Orfadin Treatment in Hypertyrosinemia Type 1 (HT-1) Patients in Standard Care
Lead sponsor
Swedish Orphan Biovitrum
Phase
Observational
Overall status
Completed
Start date
September 30, 2013
Completion date
September 30, 2019
Enrollment
315 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary tyrosinemia, type i